Clinical trial
Cancer Sequencing Guided Personalized and Precision Medicine Platform in Multiple Myeloma
NCT06338150 is registered in ClinicalTrials.gov with Icahn School of Medicine at Mount Sinai as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Cancer Sequencing Guided Personalized and Precision Medicine Platform in Multiple Myeloma
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 17, 2024
- Completion date
- April 9, 2026
- Enrollment
- 100 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.